Sequencing Therapies in EGFR-mutant NSCLC

Dr. Husain discusses how therapy sequencing has become more complex with the introduction of potent first-line combinations for EGFR-mutant NSCLC. He notes that clinicians must anticipate how early treatment decisions will shape second-line and subsequent options, particularly as resistance mechanisms diversify. Understanding these resistance patterns is crucial for selecting appropriate next-line therapies, such as targeted agents or chemotherapy-based combinations.

Dr. Husain discusses how post-progression strategies depend heavily on the initial regimen used—whether patients began on FLAURA-2 or MARIPOSA. Each pathway presents different molecular and clinical challenges upon progression. He explains that ongoing trials and translational research are working to define optimal sequencing strategies, including when to incorporate next-generation EGFR inhibitors or novel agents addressing resistance mutations.

Dr. Husain discusses how a forward-thinking approach to sequencing—guided by real-world data and molecular profiling—can extend disease control and improve survival outcomes. He emphasizes that clinicians should integrate CNS considerations, tolerability, and evolving resistance biology into each treatment decision.